RxDoctor Payments Data

Valerie Lozier

Family · Intervale, NHNPI 1891240990

Payments from drug & device makers

$1,556in general payments, 2019–2025

Across 66 payments — averaging $23.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$290
  • AstraZeneca$235
  • AbbVie$140
  • Novo Nordisk$118
  • Lilly USA, LLC$103
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$89
  • plus $581 from 14 others

What the payments were for

  • Food & beverage$1,556100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,556 in reported general payments places this provider in the 85th percentile of 713 family providers in New Hampshire.

See all family providers in New Hampshire

Medicare billing

Part B allowed, 2024
$23,544
Medicare patients
49
Services billed
520

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide11$16,478
EliquisApixaban17$14,915
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$9,439
Xtampza ErOxycodone Myristate15$7,326
Pregabalin36$1,329
Oxycodone Hcl88$1,199
Albuterol Sulfate HfaAlbuterol Sulfate57$959
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine39$875
Gabapentin97$851
Atorvastatin Calcium60$656
Orphenadrine Citrate ErOrphenadrine Citrate11$615
Omeprazole45$558
Olanzapine12$549
Levothyroxine Sodium66$499
Buprenorphine Hcl16$497

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Olanzapine$103$17,02723 claims
PfizerEliquis$20$14,91517 claims
AstraZenecaBreztri Aerosphere$235$9,43916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 713 family providers in New Hampshire.

Other family in Intervale

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →